Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): What We Know and Don't Know
| Autor: | Thomas L. Ortel, Gowthami M. Arepally |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
2019-20 coronavirus outbreak
COVID-19 Vaccines Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immunology 030204 cardiovascular system & hematology Blood Spotlight Biochemistry 03 medical and health sciences 0302 clinical medicine Immune system medicine Humans Purpura Thrombocytopenic Idiopathic Heparin SARS-CoV-2 business.industry Anticoagulants COVID-19 Disease Management Cell Biology Hematology Immunization 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | Blood |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | The development of vaccines to fight COVID-19 has been a remarkable medical achievement. However, this global immunization effort has been complicated by a rare vaccine-related outcome characterized by thrombocytopenia and thrombosis in association with platelet-activating anti–platelet factor 4 antibodies. In this Spotlight, we will discuss the recently described complication of vaccine-induced immune thrombotic thrombocytopenia (VITT) occurring in response to certain COVID-19 vaccines. Although information about this clinical condition is rapidly evolving, we will summarize our current understanding of VITT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|